Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA announced the conversion of all outstanding convertible bonds held by Atlas Special Opportunities, LLC and Atlas Capital Markets, LLC into new shares, following strong data release at the ESGCT Annual Meeting 2025. This conversion, valued at NOK 14,500,000, will increase Circio’s share capital significantly, reflecting Atlas’s confidence in Circio’s future development. The move is expected to bolster Circio’s market position and provide a positive signal to stakeholders about the company’s growth trajectory.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for advanced gene and cell therapies. Their proprietary circVec platform is designed for efficient production of multifunctional circRNA within target cells, showing significant improvements in RNA half-life and protein expression compared to conventional systems. The company also continues to develop its immuno-oncology program, TG01, targeting RAS-mutated cancers.
YTD Price Performance: 75.77%
Average Trading Volume: 2,475,789
Current Market Cap: NOK135.8M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.